Thank I to our our am progress afternoon, good highlight today's as you, all XXXX as pleased well events and and XXXX priorities during Sara, call. everyone. conference
broaden we head and cervical, melanoma, tumor During non-small platform to infiltrating lung indications and cancers. XXXX metastatic including across our neck advance continue lymphocytes multiple or TIL cell and
like melanoma, the for and candidate two ongoing product lethal our new do. responses that metastatic clinical to time like reported durable CXXXXX data treatment one and demonstrating For our we updated study from core
continue and potency from FDA essays. dialogue to a initiated learned information that with our we the So refining need
site is We've the as new for enrollment to as for top cervical two of cancer. assays our and we indications life as in and initial to which in completed non-small priority reported cancer. for and head body application, pembrolizumab activated in license validate the combination study continue cancers our and and TIL data We pursuit refine in directed checkpoint late or XXXX. the of disease, the for clinical TIL [ph] lung additional combination earlier existing inhibitors multiple BLA, advanced registration with believe stages We And broad develop work our biologics with in assays that of clinical coupled well growing of cohorts significance and LN-XXX neck across for data stage of potential cancer TIL. cell
I and activities of also furthering We needs continue manufacturing employees execute confident mission. the in to the of our strength critical all cancer toward am patients. in pre commercial on to very address to commitment this deliver our
have impressive XXX of an employees at of least nearly experience. therapy who a XX% our year We have cell
alone. On main XXXX cancer let Then first lifileucel pivotal today highlight is study melanoma recent year States the will melanoma. the skin to for I clinical update. accounting Metastatic I patients spend deaths our the I XX,XXX highlighting program call in indication. a minutes a would approximately begin each few like common will diagnosed Frederick in and with United our advanced
care has as median are about very update our corporate well metastatic provided from reached like time durability clinical be of saw. need you or on median one following enthusiastic Cohort as at used focused C-XXXXX commonly most therapies. of X to of up that alternative that treatment KOLs XX.X their patients the duration follow early we continue been a month of available response options We response, steady melanoma XXXX, January exhausted though have We In and study. not
up a present available of X% chemotherapy overall response data X, an to to only upcoming term We X option offering anti from similar post conference. population the is Cohort survival X%. and X% follow rate PDX medical intend patient currently For XX% Cohort to at to only the and long
previously events. top all priority mentioned, potency for the is on a with agreement FDA assay reaching As
B BLA. the clinical not pivotal data did reach support for FDA, on up quarter refine an our We while US agreement meeting follow for Following we continue TIL to agency the define assays of a the assays. work with on with agreement cohort during Type to the to potency fourth assays of existing our duration and year, new potency the last reached developing
until While BLA future of the with submission time depends length the on dialogue agency.
XXXX. for prepared in staying BLA We continue a submission
provide You available. when plan updates to
patients. Our program as our in this cervical been in X toward lifileucel our for both melanoma and cervical key also in Enrollment landscape submission post includes Patients a plan We in potential cohorts in new is are now BLA life to cervical of the of PDX completed. indication. both the chemotherapy, in BLA strengthen whereas the cancer. cohorts The believe step C-XXX-XX the pivotal one posts Cohort have cancer. expected in inclusion is pivotal known second BLA may of metastatic support reflect two X for and investigating the this cancer potency anti label assay Cohort and upcoming treatment submission that LN-XXX study study resolution
reminder, for a previously track granted both fast has the breakthrough and designation lifileucel and FDA cancer. cervical As therapy
a Commercial process up centralized capacity manufacturing for in to from for lengthy the cryo-preserved of the Cell patients. track place yielding completed advanced shorter, transformed equipment GMP and are meet activities on or in a rooms product. Turning in clean months. to are of was Center, Iovance XXXX demand late available remains scalable, manufacturing manufacturing Therapy XXXXs with ICTC, Process rooms of have in to construction initiate support clinical process, expected to clean our facility to XXXX. academic manufacturing coming in now to the or the a
have TIL XX process X XX%. is Gen above Our success To continuing rate a date, XXX patients than days. with more received Iovance
of of process. to compositions our GEN in built property to than leading patents have treatment methods allows X intellectual is broad international arguments by manufacturing which and more range or We XX also and the our covered on continued a granted U.S for cancers
portfolio modification, of combination patents IP and applications granted TIL stable inhibitors. and manufacturing, with gently includes checkpoint selected and Iovance products, patent TIL cryopreservation directed toward genetic and fancy Our TIL
advance Turning to education [ph] readiness TIL preparation, commercial engagement, awareness, on training, team and our activities. fight is KLO patient currently other launch activation and access focused and the
success a to Our launch to gated submission. ensure while commercial approach and be priority a taking to in is readiness, prior expenses headcount
and medical with to cancer that build A submission. that onboarding to Our partner of network healthcare to and available core or their treating training ensure groups organization. affairs capabilities commercial intensive tools skill of service TIL to and team patient upon team interest leading centers information works advocacy about a U.S HCPs, the continues the with the professionals line
have as and Our market to believe for timely well clinical value We Medicaid private the as need to CMS lifileucel. Centers with access to payers meet metastatic access appropriate Medicare and team lifileucel and CMS continues benefits and recognize unmet of patients with for the payers the or that ensure patients the potential Services, and melanoma.
program. development our are [ph] and pleased cares of progress also We the events that
new Our status, now clinical Frederick treatment deliver class, regimens assists study and the and sell a updates the in will enrollment best as of call to studies. support every the process. to goal ordering I of to existing outline cohorts patients the into step pass our is as patient at introduction including our well system that Frederick?
